GORDONSVILLE, Va., March 4 /PRNewswire/ -- A new study by researchers at
In the randomized, double-blind clinical trial, more than 5,000 women with heart disease, and at least three risk factors for cardiovascular disease, were given vitamins B6, B12, and folic acid over a seven-year time period. At the end of the trial, approximately 34 percent of the women had a lower risk of developing any type of AMD, while 41 percent had a lower risk of more severe forms of AMD.
"What's interesting here is the study authors note the correlation between age-related macular degeneration and cardiovascular disease," said nutritional expert Dr. Barbara Levine, Weill Cornell Medical College. "I recommend patients with nutritional deficiencies speak to their physicians about Animi-3, which is formulated with these essential B vitamins and DHA, the most important omega-3 fat, to address various conditions, including heart disease, arthritis, eye health, and depression."
"DHA is highly concentrated in the retina of the eye, which is one of the reasons why a DHA deficiency may be important to vision," added President Jack Schramm, PBM Pharmaceuticals, Inc., the makers of Animi-3. "Animi-3 delivers DHA as well as B6, B12, and folic acid. Studies continue to suggest that DHA, along with a combination of vitamins B6, B12, and folic acid, can address deficiencies in these nutrients associated with eye problems, including dry eye and macular health."
Each capsule of Animi-3 contains 500 mg of omega-3, (350 mg of DHA), 200 mg of phytosterols, 1 mg of folic acid, 12.5 mg of B6, and 12 mcg of B12.
More information on Animi-3 ingredients is found on www.animi-3.com and on www.dhaandbvitamins.org, a resource developed by specialists at Weill Cornell Medical College and other leading medical centers.
Animi-3 is not intended to diagnose, treat, or cure any disease.
Contact: Joe Shields Director of Public Relations (800) 959-2066 ext. 1131 email@example.com
|SOURCE PBM Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved